Celiac Disease as a Rare Cause of Membranous Nephropathy: A Case Report

Article in Cureus · February 2021
DOI: 10.7759/cureus.13312

2 authors, including:

Pedro Vieira
Hospital Central do Funchal

16 PUBLICATIONS 8 CITATIONS
SEE PROFILE
Celiac Disease as a Rare Cause of Membranous Nephropathy: A Case Report

Nicole Pestana 1, Carlota Vida 1, Pedro Vieira 1, José Durães 1, Gil Silva 1

1. Nephrology Department, Hospital Central do Funchal, Funchal, PRT

Corresponding author: Nicole Pestana, nicole.pest@gmail.com

Abstract
Membranous nephropathy is the most common cause of nephrotic syndrome in adults. A non-negligible number of cases are associated with systemic conditions. We report a case of a 50-year-old man who presented with nephrotic syndrome six months after being diagnosed with celiac disease. Although the patient showed disappearance of circulating immunoglobulin A (IgA) anti-tissue transglutaminase antibodies following a gluten-free diet, he had a sudden onset of nephrotic syndrome presenting with severe hypoalbuminemia. Other secondary causes were promptly excluded leading to the assumption of celiac disease-associated membranous nephropathy with remission after treatment with angiotensin system blockade and a gluten-free diet. The goal of this case report is to alert the clinic towards this rare association aiming for an early diagnosis and adequate selection of long-term therapy.

Introduction
Membranous nephropathy (MN) is the most common cause of nephrotic syndrome in white Caucasian adults, accounting for approximately 40% of cases [1]. MN is classically divided into two subgroups: primary and secondary MN. Secondary MN constitutes around 20% of all MN cases and occurs in the context of underlying conditions, namely malignancies, drugs, rheumatological diseases, and infections [2]. Celiac disease (CD) is one of the most common autoimmune disorders, with a reported prevalence of 0.5-1% of the general population [3]. Although the incidence of renal disease in CD patients is low and vice versa, this association has pathogenic aspects that can affect both conditions. Here we report a case of MN in a patient with CD and discuss the pitfalls of underlying investigation in this glomerular disease.

Case Presentation
The authors present a case of a 50-year-old Caucasian man with CD diagnosed in January 2020 and heavy smoking habits (>25 cigarettes a day). He was referred to Nephrology Department in June 2020 due to recent onset of generalized edema with an 8 kg weight gain and deterioration of renal function. On physical exam he was normotensive and presented with bilateral pitting edema. Laboratory findings revealed decreased renal function (serum creatinine 1.5 mg/dL as opposed to six months earlier 1 mg/dL), severe hypoalbuminemia (albumin 17 g/L) and hypertriglyceridemia (triglycerides 550 mg/dL). Urinary analysis showed proteinuria (4+) with a 24h urine protein excretion of 30 g. Kidney ultrasound was unremarkable with normal kidneys. Considering a full-blown nephrotic syndrome with massive proteinuria, a renal biopsy was performed revealing a membranous nephropathy (Figure 1).
FIGURE 1: Immunofluorescence microscopy

Granular deposition of IgG along the outer surface of capillary walls

Given his known CD and possible relationship with glomerulonephritis, analytical investigation was extended and revealed disappearance of circulating immunoglobulin A (IgA) anti-tissue transglaminase antibodies following a six-month gluten-free diet. At this point, the hypothetical diagnosis of secondary MN due to CD was temporarily postponed to exclude other further MN causes. Additional analysis revealed a low titer of antinuclear antibodies (ANA; with a non-specific nucleolar pattern) (titer 1:530) and negative anti-double-stranded DNA, rheumatoid factor, complement, anti-neutrophil cytoplasmic, and anti-phospholipase A2 receptor antibodies (anti-PLA2R). Supplementary studies to characterize the ANA pattern did not reveal any specific disease-associated autoantibodies. Nailfold capillaroscopy was performed, excluding Raynaud’s phenomenon. Hepatitis B, C, and HIV were also excluded. Thoracic and abdominal computed tomography scan, colonoscopy, and endoscopy were negative. Regarding his past medical history, the patient had never received gold salts or nonsteroidal anti-inflammatory drugs. Considering the exclusion of other secondary causes, the assumption of MN secondary to CD was made. A conservative approach was initiated by ramipril until 15 mg a day in addition to a gluten-free diet. Rituximab was considered but considering partial remission in two months to proteinuria under 6 g/day, the approach remained conservative. Although the low evidence of MN and CD association reported, the presentation of full blown nephrotic syndrome following CD diagnosis and the response to a gluten-free diet supported the diagnosis of CD-associated MN.

Discussion

The association between CD and MN is rarely reported in the literature [4]. As both are immune-mediated diseases, they possibly share an autoimmune pathogenesis with simultaneous digestive and renal involvement. Some described an increase in the number of cases of chronic glomerulonephritis and renal insufficiency in patients with CD and this risk is greater in adults [5]. By far the main association between CD and glomerular disease is IgA nephropathy (IgAN) with 22-77% of patients with IgAN having IgA antigliadin antibodies and 3-4% of these having CD [6,7]. In our case report the patient had histological evidence of MN but no IgA deposits, excluding any resemblance to IgAN. In our opinion, the link between CD and MN is not unexpected. Although there was a different temporal onset of both diseases the patient had remission of massive proteinuria followed by disappearance of circulating IgA anti-tissue transglutaminase antibodies. In fact, there was remission of both diseases, as is seen in the majority of cases of secondary MN that remit when the original cause is addressed [8]. Anti-PLA2R autoantibodies are highly specific for primary MN and are found in approximately 75% of patients at time of diagnosis [9]. We would like to emphasize that our patient had negative anti-PLA2R leading us to secondary investigation as recommended by the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines [10]. ANAs have also been found in autoimmune diseases and cancer [11,12]. Its presence although unspecific alerts us to the possibility of systemic lupus erythematosus (SLE) which has a known association with CD [13], and systemic sclerosis (SS). The absence of clinical evidence of SLE (arthralgias, cutaneous lesions, photosensitivity,
telangiectasia, hematological affection, or active urinary sediment) associated with the negative anti-DNA antibodies excludes this diagnosis. In addition, the absence of Raynaud’s phenomenon, skin changes, and unexplained dry mouth and eyes associated with negative specific antibodies disease do not contribute to the diagnosis of SS nor Sjögren syndrome. Considering this, concerns of neoplasms were raised. Cancer diagnosis accounts for 10% of secondary cases of MN, with lung and gastrointestinal systems the most frequent [14]. These are sometimes diagnosed in a non-specific nucleolar ANA pattern without identified autoantibody [12]. Regarding the patient’s heavy smoking habits, MN-associated neoplasia was promptly studied and excluded. We concluded our investigation with exclusion of specific MN-implicated drugs (gold salt drugs and anti-nonsteroidal anti-inflammatory drugs). The assumption of secondary MN associated with CD was made with the patient entering partial remission after two months of increasing angiotensin blocker therapy and continuous gluten-free diet. Literature supports our case report in which the absence of anti-PLA2R is associated with a higher likelihood of clinical remission [15].

Conclusions

Clinicians should be aware of the rare association between CD and MN. This must be considered in a patient presenting with improvement of nephrotic syndrome after angiotensin blockage therapy and gluten-free diet, despite the absence of IgA anti-tissue transglutaminase antibodies. Further studies are necessary to elucidate the possible common pathogenic mechanisms of both diseases.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Johnson R, Feehally J, Fioege J, Tonelli M: Comprehensive Clinical Nephrology. Elsevier, Amsterdam; 2018. https://www.elsevier.com/books/comprehensive-clinical-nephrology/johnson/978-0-323-47909-7.
2. Cousser WG: Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017, 12:983-997. 10.2215/CJN.11761116
3. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, Fasano A: Celiac disease: a comprehensive current review. BMC Med. 2019, 17:142. 10.1186/s12916-019-1380-z
4. Gimenez Llort A, Vila Cots J, Camacho Diaz JA, Vila Santandreu A, Concheiro Guisan A, Garcia Garcia L: Nephrotic syndrome associated with celiac disease. A report of five cases. Nephron. 2002, 92:950. 10.1159/000065576
5. Ludvigsson JF, Montgomery SM, Olen O, Elkhom A, Ludvigsson J, Fored M: Coeliac disease and risk of renal disease—a general population cohort study. Nephrol Dial Transplant. 2006, 21:1809-15. 10.1093/ndt/gfl117
6. Sategna-Guidetti C, Per foglia G, Bruno M, Pulitano R, Roccatello D, Coppo R: Do IgA antiplidin and IgA antiendomysium antibodies show there is latent coeliac disease in primary IgA nephropathy?. Gut. 1992, 33:476-8.
7. Almroth G, Axelsson T, Müssener E, Grodzinsky E, Midhagen G, Olcén P: Increased prevalence of anti-gliadin IgA-antibodies with aberrant duodenal histopathological findings in patients with IgA-nephropathy and related disorders. Ups J Med Sci. 2006, 111:359-52. 10.3109/00001967-060
8. Soro S, Sánchez de la Nietta MD, Rivera F: Celiac disease and membranous nephropathy. Nefrologia. 2009, 29:479-481. 10.3265/Nefrologia.2009.29.5.5324.en.full
9. Mastroianni-Kirsztajn G, Hornig N, Schlumberger W: Autoantibodies in renal diseases - clinical significance and recent developments in serological detection. Front Immunol. 2015, 6:221. 10.3389/fimmu.2015.00221
10. Cattrann PC, Feehally J, Cook HT, et al.: Kidney Disease: Improving Global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012, 2:129-274. 10.1038/kisp.2012.9
11. Solomon DH, Kavanaugh AJ, Schur PH: Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Care Res. 2002, 47:434-444. 10.1002/art.10561
12. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM: Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992, 140:859-70.
13. Collin P, Mäki M: Associated disorders in coeliac disease: clinical aspects. Scand J Gastroenterol. 1994, 29:769-75. 10.3109/03050529409092508
14. Lefaucher C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J: Autoimmune polyglandular syndrome type I: spectrum, association with celiac disease and functional implications. Gut. 1992, 33:479-481.
15. Caio G, Volta U, Sapone A, Leffler DA, De Giorgio R, Catassi C, Fasano A: Celiac disease: a comprehensive current review. BMC Med. 2019, 17:142. 10.1186/s12916-019-1380-z
16. Sategna-Guidetti C, Per foglia G, Bruno M, Pulitano R, Roccatello D, Coppo R: Do IgA antiplidin and IgA antiendomysium antibodies show there is latent coeliac disease in primary IgA nephropathy?. Gut. 1992, 33:476-8.
17. Almroth G, Axelsson T, Müssener E, Grodzinsky E, Midhagen G, Olcén P: Increased prevalence of anti-gliadin IgA-antibodies with aberrant duodenal histopathological findings in patients with IgA-nephropathy and related disorders. Ups J Med Sci. 2006, 111:359-52. 10.3109/00001967-060
18. Soro S, Sánchez de la Nietta MD, Rivera F: Celiac disease and membranous nephropathy. Nefrologia. 2009, 29:479-481. 10.3265/Nefrologia.2009.29.5.5324.en.full
19. Mastroianni-Kirsztajn G, Hornig N, Schlumberger W: Autoantibodies in renal diseases - clinical significance and recent developments in serological detection. Front Immunol. 2015, 6:221. 10.3389/fimmu.2015.00221
20. Cattrann PC, Feehally J, Cook HT, et al.: Kidney Disease: Improving Global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012, 2:129-274. 10.1038/kisp.2012.9
21. Solomon DH, Kavanaugh AJ, Schur PH: Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Care Res. 2002, 47:434-444. 10.1002/art.10561
22. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM: Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol. 1992, 140:859-70.
23. Collin P, Mäki M: Associated disorders in coeliac disease: clinical aspects. Scand J Gastroenterol. 1994, 29:769-75. 10.3109/03050529409092508
24. Lefaucher C, Stengel B, Nochy D, Martel P, Hill GS, Jacquot C, Rossert J: Membranous nephropathy and cancer: epidemiologic evidence and determinants of high cancer association. Kidney Int. 2006, 70:1510-7. 10.1038/sj.ki.5001790
25. Pourcine F, Dahane K, Mihout F, Cachanado M, Brocheriou I, Dehlic H, Ronco P: Prognostic value of PLAR2 autoimmunity detected by measurement of anti-PLAR antibodies combined with detection of PLAR2 antigen in membranous nephropathy: a single centre study over 14 years. PloS One. 2017, 12:e00173201. 10.1371/journal.pone.00173201